Exclusive Interview: Dr. William A. Carter, of Hemispherx Biopharma, Inc. (AMEX:HEB)

Pasadena, CA - 06/12/09 - BioMedReports.Com, the news portal covering the biomedical sector that delivers financial and investment intelligence to a community of highly informed investors has conducted an exclusive interview with Dr. William A. Carter, CEO of Hemispherx Biopharma (AMEX:HEB).

The exclusive audio interview, was conducted on Friday afternoon (06/12/09) and will be available at BioMedReports.Com at 8pm EST on Friday, June 12, 2009.

Dr. Carter, the co-inventor of Ampligen®, joined the Company in 1978, and has served as HEB’s Company’s Chief Scientific Officer since May 1989, the Chairman of the Company’s Board of Directors since January 1992, the Company’s Chief Executive Officer since July 1993, the Company’s President since April, 1995, and a director since 1987. From 1987 to 1988, Dr. Carter served as the Company’s Chairman. Dr. Carter was a leading innovator in the development of human interferon for a variety of treatment indications including various viral diseases and cancer. In this context, he received the first FDA approval to initiate clinical trials on a beta interferon product manufactured in the U.S. under his supervision.

Investors are invited to listen to the interview about the company, including questions about the pending FDA decision. The latest business developments and news involving Ampligen and Alferon in the influenze space as well as HEB’s intentions for new investments and expansion.

Visit BioMedReports.Com for more details.

Biotech investors interested in seeing the complete database of clinical trials and upcoming FDA decisions can access that information here:

http://biomedreports.com/component/content/article/548.html

Disclosure: No positions.

####

About BiomedReports.Com

BioMedReports.com is a news portal covering the biomedical news and financial sector. It features its own blog, discussion forum, stock research reports, news feeds, videos, press release capability, stock commentaries, and other unique content - including FDA and Clinical Trial Calendars plus a database that includes about 1,000 stocks and exchange-traded funds from the healthcare sector which are organized into various new healthcare stock indexes.

For more biomedical sector and investment news, go to www.BioMedReports.com

Certain sections of this report contain forward-looking statements that are based on our reporters’ expectations, estimates, projections and assumptions. Words such as “expects,” “anticipates,” “plans,” “believes,” “scheduled,” “estimates” and variations of these words and similar expressions are intended to identify forward-looking statements, which include but are not limited to projections of revenues, earnings, segment performance, cash flows, contract awards, FDA announcements, trial and drug approvals, and company stability. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is forecast in forward-looking statements due to a variety of factors including but not limited to the status or outcome of legal and/or regulatory proceedings.

All forward-looking statements speak only as of the date of this report or, in the case of any document incorporated by reference, the date of that document. All subsequent written and oral forward-looking statements attributable to the company or any person acting on the company’s behalf are qualified by the cautionary statements in this section. BiomedReports.Com does not undertake any obligation to update or publicly release any revisions to forward-looking statements to reflect events, circumstances or changes in expectations after the date of this report.

Contact Information

M.E. Garza

Editor

BiomedReports.Com

Contact via E-mail